Campus Ideaz

Share your Ideas here. Be as descriptive as possible. Ask for feedback. If you find any interesting Idea, you can comment and encourage the person in taking it forward.

EazyDetect - Genetic Marker Library for Cancer Dectection

Problem: Late detections are common for many cancers since the known genetic markers are less in number and their testing is the highest on the cost grid.

~~

Solution

I want to build an India-centric genetic marker library with the help of CRISPR technology.

First, I intend to collect and analyze data from cancer studies made in India and globally. From this we can identify the most frequently and clinically important mutations in cancers that are common in India. 

Using this we prioritize 20-30 key markers for a pilot panel. 

For the interesting part: I introduce CRISPR-Cas12 with isothermal amplification to detect these markers faster and more effectively. 

Isothermal amplification is another way of PCR where the heat is constant and not transferable between hot and cold. This means we don't need any expensive machines. CRISPR-Cas12 works with a guide RNA to look for a particular mutation/marker. 

Detection is read on a simple paper strip making it budget-friendly and portable. 

I want to start with a few markers to validate the product and then scale it.

Scalability for this idea is very high as there can be good collaborations with hospitals, rural clinics, and research labs.

I'm happy to say that this could create a national cancer marker reference for precision medicine.

Votes: 22
E-mail me when people leave their comments –

You need to be a member of campusideaz to add comments!

Join campusideaz

Comments

  • The strategy to utilize a simple paper strip for detection is highly commendable. It ensures remarkable portability and budget-friendliness, giving this technology immense scalability potential for deployment in both high-capacity hospitals and resource-limited rural clinics.
  • Your vision to create an India-centric genetic marker library is exceptionally well-aligned with the principles of precision medicine, ensuring that the diagnostic tools developed are maximally relevant and effective for the specific patient populations they aim to serve.
  • The integration of CRISPR-Cas12 with isothermal amplification is a brilliant technological choice, offering a clear path to high-speed, cost-effective, and decentralized cancer detection. This innovative approach directly addresses the financial and logistical barriers prevalent in many healthcare settings.
  • Your presentation is motivating, and the technical angle is solid. On the critical side: what about specificity? Some mutations are shared across cancers or exist in healthy people. You’ll have to carefully pick markers.
  • Nice pitch overall. But I wonder about cost breakdowns: even if the device is cheap, reagents (enzymes, guide RNAs) may still be expensive. It’d help to include a rough cost-per-test estimate in your next draft.
  • I appreciate the ambition and social impact. But CRISPR-based diagnostics are still cutting edge — there might be stability issues (e.g. shelf life of reagents) when used in rural/field settings. How will you address robustness under varying temperatures?
  • Great direction — the national reference library concept is powerful. Yet, you might want to partner with hospitals and research labs early to get clinical samples and validation support rather than trying to collect everything yourselves
  • The idea is strong and well-motivated. One thing to clarify: in which cancer types will you pilot first? Different cancers have very different mutation burdens — narrowing the scope might help you get early wins
  • Very innovative, and the portability aspect is great. A question: how many markers can you reliably test in parallel on a paper strip before the signal gets messy? Scalability might run into technical constraints.
  • This is a super cool idea — combining CRISPR, isothermal amplification, and paper strips is very clever. But have you thought about false positives/negatives? You might want to run extensive validation with real patient samples early on to check accuracy
This reply was deleted.